Immunotherapy in the Context of Aortic Valve Diseases
Open Access
- 17 July 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (6) , 1173-1185
Abstract
: Purpose: Aortic valve disease (AVD) affects millions of people around the world, with no pharmacological intervention available. Widely considered a multi-faceted disease comprising both regurgitative pathogenesis, in which retrograde blood flows back through to the left ventricle, and aortic valve stenosis, which is characterized by the thickening, fibrosis, and subsequent mineralization of the aortic valve leaflets, limiting the anterograde flow through the valve, surgical intervention is still the main treatment, which incurs considerable risk to the patient. Results: Though originally thought of as a passive degeneration of the valve or a congenital malformation that has occurred before birth, the paradigm of AVD is shifting, and research into the inflammatory drivers of valve disease as a potential mechanism to modulate the pathobiology of this life-limiting pathology is taking center stage. Following limited success in mainstay therapeutics such as statins and mineralisation inhibitors, immunomodulatory strategies are being developed. Immune cell therapy has begun to be adopted in the cancer field, in which T cells (chimeric antigen receptor (CAR) T cells) are isolated from the patient, programmed to attack the cancer, and then re-administered to the patient. Within cardiac research, a novel T cell–based therapeutic approach has been developed to target lipid nanoparticles responsible for increasing cardiac fibrosis in a failing heart. With clonally expanded T-cell populations recently identified within the diseased valve, their unique epitope presentation may serve to identify novel targets for the treatment of valve disease. Conclusion: Taken together, targeted T-cell therapy may hold promise as a therapeutic platform to target a multitude of diseases with an autoimmune aspect, and this review aims to frame this in the context of cardiovascular disease, delineating what is currently known in the field, both clinically and translationally.Keywords
Funding Information
- British Heart Foundation (CH/17/1/32804)
This publication has 137 references indexed in Scilit:
- Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial InfarctionJAMA, 2005
- Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosisJACC, 2004
- Progression of aortic valve stenosis: TGF-β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosisThe Annals of Thoracic Surgery, 2003
- Abdominal Aortic Calcific Deposits Are an Important Predictor of Vascular Morbidity and MortalityCirculation, 2001
- Monoclonal T-Cell Proliferation and Plaque Instability in Acute Coronary SyndromesCirculation, 2000
- Oxidized LDL Increases and Interferon-γ Decreases Expression of CD36 in Human Monocyte–Derived MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγCell, 1998
- Balloon aortic valvuloplasty in adults: Failure of procedure to improve long-term survivalJACC, 1995
- T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.Proceedings of the National Academy of Sciences, 1995
- Valvular heart disease: the influence of changing etiology on nosology.1994